Join our daily newsletter At The Bell to receive exclusive market insights
- INOVIQ (IIQ) and the University of Queensland (UQ) have expanded their collaboration to develop an ovarian cancer screening test
- Under a $2.7 million grant, the University of Queensland will develop an exosome-based blood test for early detection of ovarian cancer
- It will utilise INOVIQ’s EXO-NET technology for exosome isolation in thousands of blood samples
- The company will have the exclusive option to license rights to the development and commercialisation of the early detection test
- Shares were trading 0.58 per cent higher today at 85 cents each
INOVIQ (IIQ) and the University of Queensland (UQ) have expanded their collaboration to develop an ovarian cancer screening test.
Under a $2.7 million Medical Research Future Fund grant, the University of Queensland will develop an exosome-based blood test for early detection of ovarian cancer.
Exosomes contain bioactive molecules, which can reveal important information on the identification of biomarkers, diagnosis and treatment of disease.
UQ will utilise INOVIQ’s EXO-NET technology for exosome isolation in thousands of blood samples.
This technology can successfully catch exosomes from blood to enable development of diagnostic tests.
The company will have the exclusive option to license rights to the development and commercialisation of the early detection test.
Chief Executive Officer Dr Leearne Hinch said the test would improve women’s health outcomes and save lives.
“There is currently no accurate and reliable blood test available for screening ovarian cancer,” she said.
“The combination of INOVIQ’s EXO-NET technology to capture exosomes and UQ’s novel exosomal biomarkers is expected to allow significantly improved earlier and more accurate detection of ovarian cancer.”
Shares were trading 0.58 per cent higher today at 85 cents each at 12:53 pm AEDT.
